A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Cytarabine; Daunorubicin liposomal; Gemtuzumab ozogamicin; Topotecan
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 20 Aug 2013 Biomarkers information updated
- 02 Jan 2010 Unfavourable results presented in an article in the British Journal of Hematology.
- 11 Jan 2007 Status changed from in progress to completed